Rituximab as first-line treatment of pemphigus

Lancet. 2017 May 20;389(10083):1956-1958. doi: 10.1016/S0140-6736(17)30787-0. Epub 2017 Mar 22.

Author

Affiliation

¹ Department of Dermatology, University of Lübeck, Lübeck, D-23538, Germany; Lübeck Institute of Experimental Dermatology, University of Lübeck, Lübeck, Germany. Electronic address: enno.schmidt@uksh.de.

PMID: 28342636
DOI: 10.1016/S0140-6736(17)30787-0

No abstract available

MeSH terms

Antineoplastic Agents, Immunological / therapeutic use*
Clinical Trials as Topic
Female
Humans
Male
Pemphigus / drug therapy*
Recurrence
Rituximab / therapeutic use*
Treatment Outcome

Substances

Antineoplastic Agents, Immunological
Rituximab